A team of researchers from Baylor College of Medicine have identified a gene therapy that can stimulate the increase of new insulin-producing cells of the pancreas and reverse the symptoms of type 1-diabetes, according to a current presentation at the annual meeting of the Endocrine Society. In experiments with mice, the study showed the team it is feasible to stimulate gene activity neurogenin3, which requires recently formed pancreatic cells to distinguish into insulin-producing beta cells.
This solves a major challenge in the treatment of type 1 diabetes. Individuals with the condition usually is not enough beta cells, so they are constantly at a dangerously low level of insulin. However, the creation of more beta cells not only improves the condition. Because the type 1 diabetes is not a sufficient beta cells, usually because their own body immune system attacks and destroys these cells. To combat this problem, researchers have turned to gene therapy.
Their mouse model showed that adding a gene called CD274 inhibits the activity of the immune buy lexapro india system’s T cells, which are the units that often attack the beta cells of the pancreas. By combining therapies that involve the CD274 and neurogenin3 genes, the researchers showed that it is possible to regrow beta cells and prevent their destruction by the immune system in mice. The animal trials showed an 80 percent success rate.
“With just one injection of this gene therapy, the mice remain diabetes-free long term and have a return of normal insulin levels in the body,” said Vijay Yechoor, MD, the researcher of the study.
The next step in the development of treatment will be applied to humans, which is sometimes easier said than done. Prove the efficacy of treatment in mice is generally a good first step in creating a new drug, but that does not necessarily mean that the treatment method will be applicable to humans. But if further testing is successful, Yechoor says that gene therapy has the potential to be a “curative” treatment for diabetes type 1 -.